In our penultimate video from ESMO 2024, pharmaphorum spoke with Dr Magda Meissner, consultant medical oncologist at the Velindre Cancer Centre and project lead for QuicDNA, about how a sim
The top court in the EU has ruled that the European Commission exceeded its authority in its investigation of the $8 billion merger between Illumina and Grail, albeit too late to halt the f
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.